Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient

被引:25
|
作者
Solla, Paolo [1 ]
Cannas, Antonino [1 ]
Congia, Socrate [1 ]
Floris, Gianluca [1 ]
Aste, Rosa [1 ]
Tacconi, Paolo [1 ]
Marrosu, Maria Giovanna [1 ]
机构
[1] Univ Cagliari, Inst Neurol, Ctr Disordini Movimento, Dipartimento Sci Cardiovasc & Neurol,Sez Neurol, I-09124 Cagliari, Italy
关键词
Pisa syndrome; Parkinson's disease; Dystonia; Entacapone/levodopa/carbidopa combination;
D O I
10.1016/j.jns.2008.07.017
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pisa syndrome (PS) is a dystonic lateroflexion of the trunk with a postural disturbance resembling the leaning tower of Pisa. Initially reported as a side effect related to antipsychotic therapy, this original dystonic Posture is also manifested in neurodegenerative disorders such as Alzheimer's disease and multiple system atrophy, or in rare idiopathic cases. Recent observations have described the onset of PS with subchronic course in patients affected by Parkinson's disease (PD). Here, we report on the acute development of PS in a parkinsonian patient during treatment with entacapone/levodopa/carbidopa combination. This case illustrates how, in contrast to previously well-known chronic/subchronic forms, this axial dystonic posture may occur in PD as an acute onset reversible type, related to levodopa treatment. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:154 / 156
页数:3
相关论文
共 50 条
  • [1] Levodopa/carbidopa/entacapone in Parkinson's disease
    Seeberger, Lauren C.
    Hauser, Robert A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (07) : 929 - 940
  • [3] Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease
    Delea, Thomas E.
    Thomas, Simu K.
    Hagiwara, May
    Mancione, L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (07) : 1543 - 1552
  • [5] Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference
    Mueller, Thomas
    PATIENT PREFERENCE AND ADHERENCE, 2009, 3 : 51 - 59
  • [6] Levodopa/carbidopa versus levodopa/carbidopa/entacapone as a predictive factor for the development of motor complications in Parkinson's disease
    Olanow, C. W.
    Kieburtz, K.
    Rascol, O.
    Poewe, W.
    Schapira, A.
    Nissinen, H.
    Leinonen, M.
    Stocchi, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 658 - 658
  • [7] Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease
    Hauser, Robert A.
    Panisset, Michel
    Abbruzzese, Giovanni
    Mancione, Linda
    Dronamraju, Nalina
    Kakarieka, Algirdas
    MOVEMENT DISORDERS, 2009, 24 (04) : 541 - 550
  • [8] Optimization of use of levodopa in Parkinson's disease:: role of levodopa-carbidopa-entacapone combination
    Castro, A
    Valldeoriola, F
    Linazasoro, G
    Rodriguez-Oroz, MC
    Stochi, F
    Marín, C
    Rodríguez, M
    Vaamonde, J
    Jenner, P
    Alvarez, L
    Pavón, N
    Macías, R
    Luquín, MR
    Hernández, B
    Grandas, F
    Giménez-Roldán, S
    Tolosa, ES
    Obeso, EJ
    NEUROLOGIA, 2005, 20 (04): : 180 - 188
  • [9] Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone
    Park, Jongkyu
    Kim, Younsoo
    Youn, Jinyoung
    Lee, Phil H.
    Sohn, Young H.
    Koh, Seoung B.
    Lee, Jee-Young
    Baik, Jong S.
    Cho, Jin W.
    NEUROLOGY INDIA, 2017, 65 (04) : 746 - 751
  • [10] Levodopa half-life with additional carbidopa in Parkinson's disease (PD) patients treated with carbidopa/levodopa and entacapone
    Parashos, SA
    Wielinski, CL
    Peterson, SM
    Brundage, RC
    MOVEMENT DISORDERS, 2005, 20 : S89 - S90